We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VTP-600

News List

Air of optimism surrounds lung cancer vaccine pharmatimes
January 18, 2022
Cancer Research UK announces clinical trial for most common type of lung cancer
Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy b3cnewswire
December 25, 2019
Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT) ...
CRUK partners with Vaccitech on NSCLC immunotherapeutic vaccine pharmaceutical-technology
December 19, 2019
Vaccitech has signed a partnership with Cancer Research UK (CRUK) to clinically advance VTP-600, the former’s immunotherapy vaccine candidate, for patients with non-small cell lung cancer (NSCLC).